The treatment will be assessed in patients with HR+, HER2- breast cancer. Credit: Frame Stock Footage/Shutterstock.

Avenzo Therapeutics has announced a clinical trial partnership and supply agreement with Gilead Sciences to assess a combination treatment regimen for breast cancer.

The regimen includes Avenzo’s investigational CDK2 inhibitor, AVZO-021, and Gilead’s Trop-2 directed antibody-drug conjugate (ADC), Trodelvy (sacituzumab govitecan-hziy).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study will assess the combination regimen in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Under the deal, Gilead will supply Trodelvy to Avenzo, who will be responsible for conducting and sponsoring the study.

For their respective assets, both companies will maintain all development and commercial rights. This includes rights for monotherapy or combination therapies.

Avenzo Therapeutics co-founder, president and CEO Athena Countouriotis said: “We are excited to advance our oncology pipeline by entering this clinical collaboration with Gilead to evaluate the combination potential of AVZO-021.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We continue to believe AVZO-021 is a potential, best-in-class CDK2 selective inhibitor that may provide a new treatment option to patients. We look forward to initiating combination cohorts with Trodelvy, as well as CDK4/6 inhibitors, in the Phase Ib portion of the ongoing clinical study in the fourth quarter of 2024.”

In June this year, Gilead reported two-year interim data from the ongoing Phase III ASSURE study of seladelpar in patients with primary biliary cholangitis (PBC).

The open-label trial assessed the long-term safety and efficacy of seladelpar, an orally active peroxisome proliferator-activated receptor delta agonist.

The findings revealed quick and lasting improvements in cholestasis markers, with increased rates of liver biomarker normalisation and significant pruritus reduction.